ADULT T-CELL LEUKEMIA/LYMPHOMA
Clinical trials for ADULT T-CELL LEUKEMIA/LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ADULT T-CELL LEUKEMIA/LYMPHOMA trials appear
Sign up with your email to follow new studies for ADULT T-CELL LEUKEMIA/LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis phase 2 trial tests a combination of the targeted drug brentuximab vedotin plus standard chemotherapy in 48 people with CD30-positive peripheral T-cell lymphoma, a rare and aggressive blood cancer. The treatment aims to kill cancer cells more effectively by delivering a toxi…
Matched conditions: ADULT T-CELL LEUKEMIA/LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 23, 2026 12:00 UTC
-
Experimental combo targets rare leukemia in early trial
Disease control TerminatedThis early-phase trial is testing whether adding the drug lenalidomide to standard chemotherapy (EPOCH) is safe and effective for adults with a rare, aggressive blood cancer called adult T-cell leukemia-lymphoma (ATLL) linked to HTLV-1 infection. About 30 participants will receiv…
Matched conditions: ADULT T-CELL LEUKEMIA/LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 22, 2026 11:55 UTC
-
New hope for Tough-to-Treat lymphoma: experimental drug shows promise
Disease control OngoingThis study tests an experimental drug called valemetostat in people with a rare type of blood cancer (peripheral T-cell lymphoma) that has returned or not responded to prior treatments. The goal is to see if the drug can shrink tumors and how safe it is. About 155 adults will tak…
Matched conditions: ADULT T-CELL LEUKEMIA/LYMPHOMA
Phase: PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 18, 2026 11:47 UTC
-
New hope for blood cancer patients in japan?
Disease control OngoingThis study is testing a new drug called Golcadomide (BMS-986369) in about 85 people in Japan whose T-cell lymphoma has come back or not responded to treatment. The goal is to check the drug's safety and how well it works against the cancer. Participants will receive the drug and …
Matched conditions: ADULT T-CELL LEUKEMIA/LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 18, 2026 11:46 UTC
-
New drug combo aims to shrink Hard-to-Treat lymphoma
Disease control TerminatedThis early-stage trial tests whether combining two drugs, azacitidine and abatacept, can shrink tumors in adults with T-cell lymphoma that has come back or not responded to prior therapy. About 20 participants will receive the drugs in 28-day cycles for up to 13 cycles. The study…
Matched conditions: ADULT T-CELL LEUKEMIA/LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 05, 2026 12:05 UTC